How invisible illnesses overlap with autoimmune conditions. From molecular mimicry driving post-infectious autoimmunity to shared cytokine dysregulation, this dashboard maps the biological connections between invisible illnesses and classical autoimmune disease.
23.5M Americans with Autoimmune Disease
80% Female
Molecular Mimicry in 60%+
Average 4.6 Years to Diagnosis
Borrelia burgdorferi infection triggers autoimmune cascades through molecular mimicry between OspA and human LFA-1. Even after successful antibiotic clearance, persistent autoimmune inflammation drives post-treatment Lyme disease syndrome (PTLDS) in HLA-DR4-positive patients. Autoantibodies against endothelial cell growth factor and annexin A2 perpetuate vascular and joint inflammation.
SARS-CoV-2 infection produces the broadest autoantibody response ever documented for a single pathogen, with over 200 distinct autoantibodies identified across Long COVID cohorts. Spike protein molecular mimicry targets cardiac myosin, neuronal proteins, and tissue transglutaminase. Anti-interferon autoantibodies impair antiviral defense and perpetuate chronic inflammation.
ME/CFS exhibits profound immune dysregulation with autoantibodies targeting G-protein-coupled receptors (GPCRs), including beta-2 adrenergic and muscarinic M3/M4 receptors in 30-40% of patients. Natural killer cell cytotoxic dysfunction is among the most reproducible immunological findings. The failed RituxME Phase III trial suggests autoimmune subgroups rather than universal autoimmune etiology.
Fibromyalgia is being reframed from a purely central sensitization disorder to one with autoimmune underpinnings. Goebel et al. (2021) demonstrated that transferring IgG from fibromyalgia patients to mice reproduced pain sensitization, providing direct evidence for pathogenic autoantibodies. Up to 60% of patients show reduced intraepidermal nerve fiber density consistent with small fiber neuropathy.
Molecular mimicry is the primary mechanism by which infections trigger autoimmune disease. When a pathogen protein shares structural similarity with a human self-protein, the immune response against the pathogen cross-reacts with the body’s own tissues. This mechanism has been documented in over 60% of post-infectious autoimmune conditions.
A pathogen (Borrelia, SARS-CoV-2, EBV) enters the body. The immune system mounts an adaptive response, generating antibodies and T-cells targeting pathogen-specific proteins.
Pathogen proteins share amino acid sequences or 3D structural motifs with human self-proteins. For example, Borrelia OspA shares epitopes with human LFA-1, and SARS-CoV-2 spike shares motifs with cardiac myosin.
Antibodies and T-cells originally targeting pathogen antigens begin cross-reacting with structurally similar human proteins. This breaks immune tolerance to self-antigens.
The immune system sustains attack on self-tissues even after pathogen clearance. Chronic inflammation, tissue damage, and clinical symptoms of autoimmune disease develop and persist.
Known mimicry pairs: Borrelia OspA / human LFA-1 (Lyme arthritis) | SARS-CoV-2 spike / cardiac myosin (Long COVID myocarditis) | EBV EBNA-1 / GlialCAM (MS) | Group A Strep M protein / cardiac myosin (rheumatic heart disease) | Campylobacter LOS / GM1 ganglioside (Guillain-Barre)
Key autoantibodies ordered when evaluating autoimmune overlap with invisible illnesses. Understanding what each marker detects helps patients and clinicians interpret results in context.
ANA
Antinuclear Antibody
Target: Nuclear components (DNA, histones, ribonucleoproteins)
Screening test for systemic autoimmune disease. Positive in 95% of SLE, 60-80% of Sjogren's, and 15-25% of Lyme patients during active infection. Low-titer positivity is common in healthy individuals and increases with age.
Anti-CCP
Anti-Cyclic Citrullinated Peptide
Target: Citrullinated proteins in synovial joints
Highly specific (95-98%) for rheumatoid arthritis. Critically, anti-CCP is negative in Lyme arthritis, serving as the key differentiator between Lyme-induced joint inflammation and true RA. Can be positive years before RA symptom onset.
RF
Rheumatoid Factor
Target: Fc portion of IgG antibodies
Present in 70-80% of RA patients but less specific than anti-CCP. Elevated in Lyme arthritis (can mimic RA), Sjogren's syndrome, and chronic infections. Higher titers correlate with more aggressive joint disease and extra-articular manifestations.
Anti-dsDNA
Anti-double-stranded DNA
Target: Native double-stranded DNA
Highly specific for SLE (95-97% specificity). Titers correlate with disease activity, especially lupus nephritis. Useful for differentiating SLE from other ANA-positive conditions. Can appear transiently in Long COVID patients; requires monitoring for progression to clinical lupus.
Anti-TPO / Anti-Tg
Anti-Thyroid Peroxidase / Anti-Thyroglobulin
Target: Thyroid peroxidase enzyme and thyroglobulin protein
Primary markers for Hashimoto's thyroiditis and Graves' disease. Anti-TPO is present in 90-95% of Hashimoto's patients. Thyroid autoimmunity frequently co-occurs with other autoimmune conditions and with invisible illnesses: 15-20% of ME/CFS patients have subclinical thyroiditis.
Classical autoimmune diseases share significant symptom overlap with invisible illnesses, leading to diagnostic confusion and misdiagnosis. This comparison highlights shared symptoms and distinguishing features.
| Condition | Shared Symptoms | Overlap | Distinguishing Features |
|---|---|---|---|
Systemic Lupus Erythematosus (SLE) | FatigueJoint painBrain fogSkin rashesPhotosensitivity | 72% | Butterfly rash, anti-dsDNA positivity, renal involvement. SLE and Lyme disease share joint, skin, and neurological symptoms. Misdiagnosis rate between the two is 5-10%. |
Multiple Sclerosis (MS) | FatigueCognitive dysfunctionNumbness/tinglingVision changesMuscle weakness | 65% | White matter lesions on MRI, oligoclonal bands in CSF. Neuroborreliosis mimics MS in up to 8% of cases. Both Long COVID and MS involve demyelination and neuroinflammation. |
Rheumatoid Arthritis (RA) | Joint pain/swellingMorning stiffnessFatigueLow-grade fever | 58% | Symmetric polyarthritis, anti-CCP positive, bony erosions on imaging. Lyme arthritis presents with intermittent monoarthritis (typically knee) and is anti-CCP negative, the critical differentiator. |
Hashimoto's Thyroiditis | FatigueBrain fogWeight changesCold intoleranceDepression | 78% | Anti-TPO/anti-Tg positive, TSH elevation, thyroid ultrasound changes. Hashimoto's co-occurs with ME/CFS in 15-20% of patients. Thyroid dysfunction exacerbates invisible illness symptoms. |
Sjogren's Syndrome | FatigueJoint painDry eyes/mouthNeuropathyCognitive dysfunction | 70% | Anti-SSA/SSB antibodies, reduced salivary flow, lip biopsy showing lymphocytic infiltration. Sjogren's is the autoimmune condition most frequently comorbid with fibromyalgia (30% overlap). |
Autoimmune diseases disproportionately affect women. X-chromosome dosage effects, estrogen-mediated immune modulation, and microchimerism contribute to the striking sex disparity across both classical autoimmune diseases and invisible illnesses.
SLE
9:1
Female:Male
ME/CFS
3:1
Female:Male
Long COVID
1.9:1
Female:Male
Relative involvement of key autoimmune mechanisms across invisible illness conditions (0-100 scale based on published literature prevalence and strength of evidence).
Current and planned clinical trials investigating autoimmune mechanisms in invisible illnesses.
Sponsor: Berlin Cures
Target: Long COVID with GPCR autoantibodies
Aptamer-based neutralization of functional autoantibodies against GPCRs
Est. completion: Q2 2027
Sponsor: NIH/NIAID
Target: SLE, Systemic sclerosis with invisible illness overlap
Anti-CD19 CAR-T cells to eliminate autoreactive B-cell lineages
Est. completion: Q4 2027
Sponsor: NIH RECOVER
Target: ME/CFS with T-regulatory cell deficit
Low-dose IL-2 to expand Treg populations and restore immune tolerance
Est. completion: Q1 2027
Sponsor: argenx
Target: Autoimmune POTS with anti-adrenergic/muscarinic Ab
FcRn blockade to accelerate IgG catabolism and reduce pathogenic autoantibodies
Est. completion: Q3 2028
Sponsor: NIAID / Anokion
Target: PTLDS with OspA/LFA-1 cross-reactivity
Nanoparticle-delivered tolerogenic peptides to re-establish self-tolerance
Est. completion: Q2 2028
Sponsor: NIH RECOVER
Target: Long COVID with persistent cytokine elevation
JAK1/JAK2 inhibition to suppress IFN-gamma, IL-6, and TNF-alpha signaling
Est. completion: Q4 2026
Advanced immunological markers used in research and clinical practice to characterize autoimmune mechanisms in invisible illness.
IL-6 (Interleukin-6)
Pro-inflammatory cytokine central to acute phase response. Elevated IL-6 drives CRP production, fever, and systemic inflammation.
TNF-alpha
Master regulator of inflammatory cascades. Activates NF-kB pathway, induces apoptosis, and promotes leukocyte recruitment.
IFN-gamma
Type II interferon critical for Th1 immunity. Dysregulation leads to macrophage hyperactivation and tissue damage.
IL-17A
Pro-inflammatory cytokine from Th17 cells. Drives neutrophil recruitment and mucosal barrier inflammation.
C3
Central complement component. Low levels indicate consumption by immune complexes or classical pathway activation.
C4
Classical pathway component. Persistently low C4 may indicate hereditary complement deficiency or active classical pathway consumption.
C4d / sC5b-9
Complement activation fragments. C4d indicates complement deposition on tissues; sC5b-9 (membrane attack complex) indicates terminal complement activation.
CD4+ / CD8+ Ratio
Normal ratio is 1.5-2.5. Inverted ratio suggests chronic viral activation or immune exhaustion. Elevated ratio suggests autoimmune activation.
T-regulatory Cells (CD4+CD25+FoxP3+)
Suppress autoimmune responses and maintain self-tolerance. Reduced Treg numbers or function enable autoreactive T-cell escape.
Exhausted T-cells (PD-1+/Tim-3+/LAG-3+)
T-cells expressing inhibitory checkpoint receptors, indicating chronic antigen stimulation and functional impairment.
Th17/Treg Balance
The Th17/Treg ratio determines the balance between pro-inflammatory autoimmune drive and immune suppression. Skewing toward Th17 promotes autoimmunity.
Immunomodulation via Fc receptor saturation, anti-idiotype antibodies, and complement scavenging
Multiple case series show improvement in autoimmune POTS and small fiber neuropathy. Randomized trials in ME/CFS have been mixed. Cost ($5,000-$10,000/month) and insurance coverage remain barriers. Subcutaneous (SCIG) administration improving accessibility.
Physical removal of pathogenic autoantibodies, immune complexes, and cytokines from circulation
Case reports and small series demonstrate improvement in autoimmune POTS and Long COVID. The Berlin Cures apheresis protocol showed benefit in Long COVID patients with elevated autoantibodies. Temporary effect requires repeated sessions. INUSpheresis gaining attention for broader immune complex removal.
Transient opioid receptor blockade upregulates endorphins and modulates glial cell activation, reducing neuroinflammation
Multiple small RCTs show 30-40% symptom improvement in fibromyalgia (Younger et al., 2013). Widely used off-label at 1.5-4.5mg doses. Generally well-tolerated with minimal side effects. Large-scale RCTs still needed but challenging to fund for a generic drug.
B-cell depletion via CD20 targeting, reducing autoantibody production
Initial open-label trials in ME/CFS (Fluge & Mella) showed 64% response rate, but Phase III RituxME trial failed primary endpoint. May benefit autoimmune subgroups identifiable by biomarkers. Used successfully in individual autoimmune POTS and SFN cases. Risk of progressive multifocal leukoencephalopathy (PML) limits widespread use.
Block Janus kinase signaling, suppressing multiple pro-inflammatory cytokine pathways simultaneously
Baricitinib showed benefit in acute COVID-19 (ACTT-2 trial) and is being investigated for Long COVID. JAK inhibition targets the cytokine storm and interferon dysregulation central to post-infectious autoimmunity. Tofacitinib case reports in refractory ME/CFS show promise. Infection risk and cost are concerns for long-term use.
Targeted blockade of specific pro-inflammatory cytokines driving chronic immune activation
Tocilizumab (anti-IL-6R) showed benefit in COVID-19 cytokine storm and is under investigation for Long COVID. Anti-TNF agents (infliximab, adalimumab) have anecdotal reports of benefit in post-Lyme and ME/CFS. Targeted cytokine blockade may be most effective when guided by individual cytokine profiling. Risk of immunosuppression requires careful patient selection.
Chimeric antigen receptor T-cell therapy, originally developed for cancer, is being repurposed for autoimmune disease. Anti-CD19 CAR-T has achieved drug-free remission in refractory lupus (Mackensen et al., 2022). Trials are expanding to other autoantibody-mediated conditions. If autoimmune subgroups of ME/CFS, POTS, and fibromyalgia can be precisely defined, CAR-T could offer durable remission by eliminating autoreactive B-cell lineages.
Antigen-specific immune tolerance aims to reprogram the immune system to stop attacking self-proteins without broad immunosuppression. Approaches include tolerogenic dendritic cells, peptide-MHC nanoparticles (Navacims), and inverse vaccines. Anokion's ENP technology has entered trials for celiac disease. Application to molecular mimicry targets (OspA/LFA-1 in Lyme, spike/cardiac myosin in Long COVID) could provide precision treatment.
The gut microbiome directly modulates autoimmune risk through molecular mimicry between commensal antigens and self-proteins, regulatory T-cell induction via short-chain fatty acids, and intestinal barrier integrity. Fecal microbiota transplantation (FMT) is being investigated for autoimmune conditions. Precision probiotics targeting Faecalibacterium prausnitzii and Akkermansia muciniphila show immunomodulatory potential in preliminary trials.
Single-cell RNA sequencing and mass cytometry (CyTOF) are enabling immune phenotyping at unprecedented resolution. The Human Cell Atlas and NIH RECOVER initiative are mapping immune cell states across post-infectious and autoimmune conditions. Machine learning classifiers trained on multi-omic immune profiles can identify autoimmune subgroups within heterogeneous conditions like ME/CFS and Long COVID, enabling targeted treatment selection rather than empiric immunosuppression.